metformin has been researched along with Emesis in 18 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 9.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 5.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| " We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b." | 4.95 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. ( Abd El Aziz, MS; Bettge, K; Kahle, M; Meier, JJ; Nauck, MA, 2017) |
| "Digestive disorders (diarrhoea, vomiting) represent the most common metformin side-effects (around 30%) with this first-line drug treatment for type 2 diabetes." | 4.87 | Metformin and digestive disorders. ( Bouchoucha, M; Cohen, R; Uzzan, B, 2011) |
| " People who received PEX168 alone or with metformin showed more common gastrointestinal adverse effects, especially nausea and vomiting (p < 0." | 3.01 | Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. ( Abd-Elgawad, M; Abdelhaleem, IA; Abo-Elnour, DE; Abualkhair, KA; Elsayed, E; Hasan, MT; Mahmoud, A; Marey, A; Salamah, HM, 2023) |
| "Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design." | 2.94 | Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020) |
| " The most frequent adverse reactions in the PEX168 groups were mild to moderate dose-dependent gastrointestinal reactions." | 2.84 | Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. ( Chen, X; Cheng, Q; Jiang, H; Li, X; Li, Y; Lu, D; Lv, X; Peng, Y; Piao, C; Sun, L; Xiao, X; Xie, Y; Yang, G; Yang, J; Yang, W; Zhang, X; Zheng, S, 2017) |
| " Subjects were monitored for adverse events (AEs) throughout the study and 4-week follow-up." | 2.75 | Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. ( Asnaghi, V; Balena, R; Boldrin, M; Kapitza, C; Nauck, M; Ratner, R, 2010) |
| "Exenatide added to TZDs alone or in combination with metformin significantly improved glycaemic control as determined by significant improvement in HbA(1c) without associated hypoglycaemia." | 2.75 | A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. ( Cao, D; Liutkus, J; Northrup, J; Norwood, P; Pop, L; Rosas Guzman, J; Trautmann, M, 2010) |
| "Metformin XR was well tolerated; gastrointestinal side effects were more common with metformin XR vs." | 2.71 | Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-c ( Brazg, RL; Bruce, S; Fujioka, K; Joyal, S; Pans, M; Raz, I; Swanink, R, 2005) |
| "The latter can provoke an acute renal failure, which may lead to a toxic accumulation of these pharmacological agents and/or increase their nephrotoxicity." | 1.46 | [Importance of stopping some medications in case of gastrointestinal disturbances leading to dehydration]. ( Krzesinski, JM; Scheen, AJ, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mehrpour, O | 1 |
| Saeedi, F | 1 |
| Hoyte, C | 1 |
| Hadianfar, A | 1 |
| Nakhaee, S | 1 |
| Brent, J | 1 |
| Salamah, HM | 1 |
| Marey, A | 1 |
| Elsayed, E | 1 |
| Hasan, MT | 1 |
| Mahmoud, A | 1 |
| Abualkhair, KA | 1 |
| Abo-Elnour, DE | 1 |
| Abdelhaleem, IA | 1 |
| Abd-Elgawad, M | 1 |
| Gulati, S | 1 |
| Desai, J | 1 |
| Palackdharry, SM | 1 |
| Morris, JC | 1 |
| Zhu, Z | 1 |
| Jandarov, R | 1 |
| Riaz, MK | 1 |
| Takiar, V | 1 |
| Mierzwa, M | 1 |
| Gutkind, JS | 1 |
| Molinolo, A | 1 |
| Desai, PB | 1 |
| Sadraei, NH | 1 |
| Wise-Draper, TM | 1 |
| Krzesinski, JM | 1 |
| Scheen, AJ | 1 |
| Wysham, C | 1 |
| Grimm, M | 1 |
| Chen, S | 1 |
| Kalantar-Zadeh, K | 1 |
| Uppot, RN | 1 |
| Lewandrowski, KB | 1 |
| Matyjaszek-Matuszek, B | 1 |
| Lenart-Lipińska, M | 1 |
| Rogalska, D | 1 |
| Nowakowski, A | 1 |
| Chen, X | 1 |
| Lv, X | 1 |
| Yang, G | 1 |
| Lu, D | 1 |
| Piao, C | 1 |
| Zhang, X | 1 |
| Jiang, H | 1 |
| Xie, Y | 1 |
| Yang, J | 1 |
| Li, X | 1 |
| Li, Y | 2 |
| Xiao, X | 1 |
| Sun, L | 1 |
| Zheng, S | 1 |
| Cheng, Q | 1 |
| Peng, Y | 1 |
| Yang, W | 1 |
| Broglio, F | 1 |
| Mannucci, E | 1 |
| Napoli, R | 1 |
| Nicolucci, A | 1 |
| Purrello, F | 1 |
| Nikonova, E | 1 |
| Stager, W | 1 |
| Trevisan, R | 1 |
| Bettge, K | 1 |
| Kahle, M | 1 |
| Abd El Aziz, MS | 1 |
| Meier, JJ | 1 |
| Nauck, MA | 1 |
| Ratner, R | 1 |
| Nauck, M | 1 |
| Kapitza, C | 1 |
| Asnaghi, V | 1 |
| Boldrin, M | 1 |
| Balena, R | 1 |
| Liutkus, J | 1 |
| Rosas Guzman, J | 1 |
| Norwood, P | 1 |
| Pop, L | 1 |
| Northrup, J | 1 |
| Cao, D | 1 |
| Trautmann, M | 1 |
| Bouchoucha, M | 1 |
| Uzzan, B | 1 |
| Cohen, R | 1 |
| Pujante Alarcón, P | 1 |
| Hellín Gil, MD | 1 |
| Román, LM | 1 |
| Ferrer Gómez, M | 1 |
| García Zafra, MV | 1 |
| Tébar Massó, J | 1 |
| Fujioka, K | 1 |
| Brazg, RL | 1 |
| Raz, I | 1 |
| Bruce, S | 1 |
| Joyal, S | 1 |
| Swanink, R | 1 |
| Pans, M | 1 |
| Zinman, B | 1 |
| Hoogwerf, BJ | 1 |
| Durán García, S | 1 |
| Milton, DR | 1 |
| Giaconia, JM | 1 |
| Kim, DD | 1 |
| Trautmann, ME | 1 |
| Brodows, RG | 1 |
| Ribera, L | 1 |
| González-Clemente, JM | 1 |
| López Alba, T | 1 |
| Almirall, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.[NCT00460941] | Phase 2 | 133 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin[NCT00603239] | Phase 3 | 165 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin[NCT00099320] | Phase 3 | 182 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in homeostatic model assessment-beta cell (HOMA-B) from baseline to endpoint (Week 26) (outcome measure is presented as the ratio of endpoint HOMA-B divided by baseline HOMA-B). HOMA-B is a measure of pancreatic beta-cell function. (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | ratio (Geometric Mean) |
|---|---|
| Exenatide Twice Daily (BID) | 1.08 |
| Placebo | 0.84 |
Change in body weight from baseline to endpoint (26 weeks) (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | kg (Least Squares Mean) |
|---|---|
| Exenatide Twice Daily (BID) | -1.43 |
| Placebo | -0.75 |
Change in FSG from baseline to endpoint (26 weeks) (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Exenatide Twice Daily (BID) | -0.65 |
| Placebo | 0.37 |
Change in HbA1c from baseline to endpoint after 26 weeks of treatment (i.e., HbA1c at endpoint minus HbA1c at baseline) (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| Exenatide Twice Daily (BID) | -0.84 |
| Placebo | -0.10 |
Change in homeostatic model assessment-insulin sensitivity (HOMA-S) from baseline to endpoint (26 weeks) (outcome measure is presented as the ratio of endpoint HOMA-S divided by baseline HOMA-S). (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Exenatide Twice Daily (BID) | 1.09 |
| Placebo | 1.07 |
Change in waist circumference from baseline to endpoint (26 weeks) (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | cm (Mean) |
|---|---|
| Exenatide Twice Daily (BID) | -2.26 |
| Placebo | -1.85 |
Overall number of subjects who experienced an episode of minor hypoglycemia. (NCT00603239)
Timeframe: 26 weeks
| Intervention | Participants (Number) |
|---|---|
| Exenatide Twice Daily (BID) | 4 |
| Placebo | 1 |
Percentage of ITT patients who had achieved HbA1c <= 6.5% at endpoint (Week 26 or early discontinuation) (NCT00603239)
Timeframe: 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Exenatide Twice Daily (BID) | 33.6 |
| Placebo | 13.0 |
Percentage of intent-to-treat (ITT) patients who had HbA1c > 7% at baseline that decreased to <= 7% at endpoint (Week 26 or early discontinuation) (NCT00603239)
Timeframe: 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Exenatide Twice Daily (BID) | 49.0 |
| Placebo | 36.5 |
EQ-5D Score - change from baseline to endpoint (26 weeks). EQ-5D is a 5-item questionnaire used to characterize current health states. The tool and accompanying visual analog scale (VAS) assess 5 domains of quality of life, including mobility, self-care, usual activity, pain, and anxiety/depression. Weights are used to score the responses to the 5 domains, with 3 options possible in each domain: extreme problems, some/moderate problems, or no problems. Scores range from 0 to 1, with a score of 1 representing a perfect health state. (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change in Health State Score | Change in Mobility component | Change in Self Care component | Change Usual Activities component | Change in Pain/Discomfort component | Change in Anxiety/Depression component | |
| Exenatide Twice Daily (BID) | 0.79 | 0.14 | 0.08 | 0.17 | 0.29 | -0.10 |
| Placebo | -2.94 | 0.15 | 0.03 | 0.19 | 0.23 | -0.26 |
"IWQOL-Lite analysis of change from baseline to endpoint (26 weeks). IWQOL-Lite is a 31-item questionnaire, assessing the domains of physical function, self-esteem, sexual life, public distress, and work. Response categories for each item range from 1 = never true to 5 = always true." (NCT00603239)
Timeframe: baseline and 26 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change in Total Score | Change in Physical Function component | Change in Self-Esteem component | Change in Sexual Life component | Change in Public Distress component | Change in Work component | |
| Exenatide Twice Daily (BID) | -1.56 | -3.84 | 0.20 | 0.12 | -0.48 | -0.91 |
| Placebo | 0.11 | -1.05 | -0.54 | 5.01 | -0.28 | 0.08 |
5 reviews available for metformin and Emesis
| Article | Year |
|---|---|
Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nausea; Randomized Controlled Tri | 2023 |
Once weekly exenatide: efficacy, tolerability and place in therapy.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration | 2013 |
Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Femal | 2017 |
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Exenatide; | 2017 |
Metformin and digestive disorders.
Topics: Bile Acids and Salts; Diabetes Mellitus, Type 2; Diarrhea; Digestive System Diseases; Glucose; Human | 2011 |
8 trials available for metformin and Emesis
| Article | Year |
|---|---|
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch | 2013 |
Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2017 |
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Dou | 2010 |
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypo | 2010 |
[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Topics: Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Combined Modality Therapy; | 2012 |
Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-c
Topics: Adult; Aged; Blood Glucose; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 2005 |
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind M | 2007 |
5 other studies available for metformin and Emesis
| Article | Year |
|---|---|
Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States.
Topics: Abdominal Pain; Acidosis; Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diarrhea; D | 2022 |
[Importance of stopping some medications in case of gastrointestinal disturbances leading to dehydration].
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Dehydration; Humans; Hypoglycemic Agen | 2017 |
Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.
Topics: Abdominal Pain; Acidosis, Lactic; Confusion; Diabetes Mellitus, Type 2; Diagnosis, Differential; Fem | 2013 |
Summaries for patients. Exenatide therapy for type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; F | 2007 |
[Fatal lactic acidosis due to metformin in a male with type 2 diabetes mellitus and dehydration. Comments about a patient information leaflet].
Topics: Acidosis, Lactic; Aged; Dehydration; Diabetes Mellitus, Type 2; Drug Labeling; Emergencies; Humans; | 2002 |